Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Kidney disease is an epidemic clinical problem causing significant morbidity and mortality, and current treatments are limited to renin-angiotensin system blockade or renal replacement therapy for the majority of affected individuals.
|
29605557 |
2018 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice.
|
10081615 |
1999 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin genes in renal development and the occurrence and progression of renal diseases.
|
10192247 |
1999 |
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Renin-angiotensin-aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients.
|
21421655 |
2011 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin-aldosterone system inhibitors (RAASIs), including angiotensin-converting enzyme inhibitors, angiotensin AT1 receptor blockers and mineralocorticoid receptor antagonists (MRAs), are the cornerstone for the treatment of cardiovascular and renal diseases.
|
28541811 |
2017 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin-aldosterone system (RAAS) plays important roles in regulating renal hemodynamics and functions, as well as in the pathophysiology of hypertension and renal disease.
|
29600408 |
2018 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin-aldosterone system (RAAS) plays a central role in renal disease progression.
|
29882088 |
2019 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin aldosterone system inhibitors are for a long time extensively used for the treatment of cardiovascular and renal diseases.
|
30681344 |
2019 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin system inhibitors (RAS) drugs have a proteinuria-reducing effect that could prevent the progression of kidney disease in diabetic patients.
|
30817790 |
2019 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin-aldosterone blockers have been known to have the benefits of delaying onset and progression of diabetic complications including nephropathy.
|
30864083 |
2019 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present.
|
31742881 |
2020 |
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A novel REN gene mutation resulted in an alteration in the amino acid sequence of the renin signal sequence and caused childhood anemia, polyuria, and kidney disease.
|
21084044 |
2010 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Abbreviations BMI = body mass index BP = blood pressure CH = hypertensive crisis ContrHT = controlled hypertensive DBP = diastolic blood pressure GFR = glomerular filtration rate HbA1c = glycated hemoglobin HDLc = high-density lipoprotein cholesterol HE = hypertensive emergency HPLC = high-performance liquid chromatography HR = heart rate HU = hypertensive urgency JNC 7 = VII Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure LDLc = low-density lipoprotein cholesterol MDRD = Modification of Diet in Renal Disease NT = normotensive RASB = renin-angiotensin system blockers SBP = systolic blood pressure TC = total cholesterol TG = triglycerides.
|
28569557 |
2017 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Albuminuria is an early marker of kidney disease in patients with diabetes and/or hypertension undetected or untreated albuminuria is a leading cause of chronic kidney disease and cardiovascular events, The purpose of the present survey was to assess the prevalence of albuminuria in patients with diabetes and hypertension, treated with a combinations of renin angiotensin aldosterone system inhibitors and dihydropyridine calcium channel blockers.
|
30327190 |
2018 |
Kidney Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although the expression of renin and angiotensin-converting enzyme in experimental and human renal disease has been well characterized, no information is available regarding human angiotensin type 1 (AT1) receptor expression.
|
10073605 |
1999 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Among patients with proteinuric chronic kidney disease (CKD), current guideline recommendations mandate the use of agents blocking the renin angiotensin aldosterone system (RAAS) as first-line antihypertensive therapy based on randomized trials demonstrating that RAAS inhibitors are superior to other antihypertensive drug classes in slowing nephropathy progression to end-stage renal disease.
|
29276100 |
2018 |
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin II and aldosterone are the main effectors of the renin-angiotensin aldosterone system (RAAS) and have a central role in hypertension as well as cardiovascular and renal disease.
|
31425690 |
2019 |
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin II, the most vasoactive component of the renin-angiotensin-aldosterone (RAAS) pathway, can contribute to renal disease by causing an increase in arterial blood pressure leading to glomerular injury and fibrosis.
|
18206321 |
2008 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme 2 (ACE2) is a recently described member of the renin-angiotensin system that hydrolyzes angiotensin (Ang) II to Ang-(1-7), and may thereby protect against cardiovascular and renal diseases.
|
28116710 |
2017 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Animal studies show that the renin-angiotensin system contributes to hypertension, glomerulosclerosis and progressive chronic renal failure in renal disease.
|
7700001 |
1994 |
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
As angiotensin II increases glomerular pressure, we studied the relationship between genetic polymorphisms in the renin-angiotensin system-angiotensin I converting enzyme (ACE), angiotensinogen (AGT), and angiotensin II, subtype 1, receptor-and the renal involvement of insulin-dependent diabetic subjects with proliferative retinopathy: those exposed to the risk of nephropathy due to diabetes.
|
9120002 |
1997 |
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
As the intrarenal renin-angiotensin system might also be activated in this setting, we determined the ACE genotype together with other risk factors for the development of diabetic nephropathy in 122 patients with IDDM from a single centre with (n = 63) and without (n = 59) nephropathy.
|
9084972 |
1997 |
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Baseline data were used to describe patient characteristics and compare the adherence to ADA (American Diabetes Association) and KDIGO (Kidney Disease: Improving Global Outcomes) guidelines with respect to metabolic and blood pressure control, use of renin-angiotensin system-blocking agents, statins and acetylsalicylic acid between the countries.
|
30238781 |
2019 |
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors and/or angiotensin II type 1 receptor blockers is the most effective treatment to achieve these purposes in non-diabetic and diabetic proteinuric renal diseases.
|
28482281 |
2017 |
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Clinical and experimental studies that discuss the different immune functions of the renin-angiotensin system (RAS) in kidney diseases were reviewed, with emphasis on studies of kidney transplantation.
|
19539879 |
2009 |